Gastrostomy Tube Feeding Devices Market is poised to exhibit a steady growth rate between 2023 and 2032 driven by the growing geriatric population, coupled with the high incidences of chronic conditions globally. Since insufficient nutrition is associated with high mortality, ICU admissions, as well as longer hospital stays, healthcare establishments are providing early enteral nutrition to critically ill hospitalized patients.
These devices are inserted through the stomach and directly take the food to the intestine. Since gastrostomy tubes are comparatively easier to use than nasogastric tubes, the percutaneous endoscopic gastrostomy market share is on the rise. These devices are also utilized during outpatient procedures because their use does not require an overnight stay.
By age group, the pediatrics segment is likely to hold a substantial portion of the gastrostomy tube feeding devices market through the assessment timeline on account of the rising number of premature births worldwide. According to the World Health Organization, an estimated 15 million infants are born prematurely each year (before the completion of 37 weeks of gestation) and preterm birth complications are the leading cause of death among children below the age of five. Feeding difficulties are a frequent occurrence among preterm and sick babies. They often need a gastrostomy feeding nursing procedure, as they are too small or/and sick to be bottle-fed or breastfed at first.
The gastrostomy tube feeding devices market for the neurological disorders segment is expected to record a notable increase in revenue through 2032. Weight loss and malnutrition are common among patients with motor neuron disease, Alzheimer’s, Parkinson’s, and other neurological disorders. To minimize the risk of mortality, morbidity, and disability amongst these patients, interventional nutritional support using these feeding devices is provided by healthcare personnel.
After the COVID-19 outbreak, several patients have been relying on home enteral nutrition. Thus, the industry expansion from the home care segment is slated to witness exponential gains by 2032. Home enteral nutrition (HEN) is utilized in patients who have a functioning GI tract and may receive therapy outside of an intensive care environment. There has been a transition from prolonged inpatient therapy to treatment at home owing to the mounting pressure on hospitals to reduce escalating healthcare expenses and the COVID-19 pandemic. As a result, there is an increase in the demand for home-based nutritional care, which is likely to promote the home care segment growth through 2032.
Regionally, the Europe gastrostomy tube feeding devices market is anticipated to grow substantially through 2032 owing to the expanding geriatric population across Germany, the U.K., Sweden, Bulgaria, and Italy. The high burden of cancer across EU countries is facilitating product uptake across the enteral feeding devices sector. Cancer patients often struggle to maintain proper nutrition. If a person has cancer in the neck or head area, they can have trouble swallowing food. Many cancer patients are malnourished during or before cancer treatment, such as chemotherapy, surgery, or radiation therapy. Others might be diagnosed with fistulas or an abscess (an opening) in the esophagus, which makes digestion difficult.
Moog, Boston Scientific Corporation, Abbott Nutrition, Halyard Health, C.R. Bard, Fresenius Kabi, Medtronic, Nestle, and Danone are some leading manufacturers of gastrostomy tube feeding devices worldwide.